{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:58:11Z","timestamp":1790963891451,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guardant Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14117-9","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:06:18Z","timestamp":1753200378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach"],"prefix":"10.1186","volume":"25","author":[{"given":"Andrew J.","family":"Pellatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reagan M.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sante","family":"Gnerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Raghav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Parseghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Pia","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhulika","family":"Eluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leylah M.","family":"Drusbosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van K.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"14117_CR1","first-page":"233","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233\u201354.","journal-title":"CA Cancer J Clin"},{"key":"14117_CR2","doi-asserted-by":"crossref","unstructured":"Clifton K, Rich TA, Parseghian C, et al. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay [Internet]. JCO precision oncology 3, 2019[cited 2024 Dec 17] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33015522\/","DOI":"10.1200\/PO.19.00141"},{"key":"14117_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrc3947","volume":"15","author":"F Mertens","year":"2015","unstructured":"Mertens F, Johansson B, Fioretos T, et al. The emerging complexity of gene fusions in cancer. Nat Rev Cancer. 2015;15:371\u201381.","journal-title":"Nat Rev Cancer"},{"key":"14117_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/2643-3249.BCD-20-0078","volume":"1","author":"T Sadras","year":"2020","unstructured":"Sadras T, M\u00fcschen M. MEF2D fusions drive oncogenic Pre-BCR signaling in B-ALL. Blood Cancer Discov. 2020;1:18\u201320.","journal-title":"Blood Cancer Discov"},{"key":"14117_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","volume":"6","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond\u2013exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol. 2009;6:535\u201343.","journal-title":"Nat Rev Clin Oncol"},{"key":"14117_CR6","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.21873\/anticanres.15671","volume":"42","author":"J Polivka","year":"2022","unstructured":"Polivka J, Svajdler M, Priban V, et al. Oncogenic fusions in gliomas: an institutional experience. Anticancer Res. 2022;42:1933\u20139.","journal-title":"Anticancer Res"},{"key":"14117_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3390\/ijms23020689","volume":"23","author":"S Nagasawa","year":"2022","unstructured":"Nagasawa S, Ikeda K, Shintani D, et al. Identification of a novel oncogenic fusion gene SPON1-TRIM29 in clinical ovarian cancer that promotes cell and tumor growth and enhances chemoresistance in A2780 cells. Int J Mol Sci. 2022;23:689.","journal-title":"Int J Mol Sci"},{"key":"14117_CR8","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.3390\/ijms22094791","volume":"22","author":"A Newtson","year":"2021","unstructured":"Newtson A, Reyes H, Devor EJ, et al. Identification of novel fusion transcripts in high grade serous ovarian cancer. Int J Mol Sci. 2021;22:4791.","journal-title":"Int J Mol Sci"},{"key":"14117_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","volume":"17","author":"D Salvatore","year":"2021","unstructured":"Salvatore D, Santoro M, Schlumberger M. The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol. 2021;17:296\u2013306.","journal-title":"Nat Rev Endocrinol"},{"key":"14117_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41586-021-04135-5","volume":"600","author":"H Izumi","year":"2021","unstructured":"Izumi H, Matsumoto S, Liu J, et al. The CLIP1\u2013LTK fusion is an oncogenic driver in non-small\u2010cell lung cancer. Nature. 2021;600:319\u201323.","journal-title":"Nature"},{"key":"14117_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"X Du","year":"2018","unstructured":"Du X, Shao Y, Qin H, et al. ALK-rearrangement in non\u2010small\u2010cell lung cancer (NSCLC). Thorac Cancer. 2018;9:423\u201330.","journal-title":"Thorac Cancer"},{"key":"14117_CR12","doi-asserted-by":"crossref","unstructured":"Laskin J, Liu S V, Tolba K, et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents [Internet]. Annals of oncology: official journal of the European Society for Medical Oncology 31, 2020[cited 2024 Dec 17] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32916265\/","DOI":"10.1016\/j.annonc.2020.08.2335"},{"key":"14117_CR13","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1038\/s41467-022-33718-7","volume":"13","author":"JT Topham","year":"2022","unstructured":"Topham JT, Tsang ES, Karasinska JM, et al. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Nat Commun. 2022;13:5941.","journal-title":"Nat Commun"},{"key":"14117_CR14","doi-asserted-by":"publisher","first-page":"viii16","DOI":"10.1093\/annonc\/mdz384","volume":"30","author":"JP Solomon","year":"2019","unstructured":"Solomon JP, Benayed R, Hechtman JF, et al. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30:viii16\u201322.","journal-title":"Ann Oncol"},{"key":"14117_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/cncr.32649","volume":"126","author":"M Nikanjam","year":"2020","unstructured":"Nikanjam M, Okamura R, Barkauskas DA, et al. Targeting fusions for improved outcomes in oncology treatment. Cancer. 2020;126:1315\u201321.","journal-title":"Cancer"},{"key":"14117_CR16","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","volume":"27","author":"J Kim","year":"2021","unstructured":"Kim J, Bradford D, Larkins E, et al. FDA approval summary: Pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res. 2021;27:5452\u20136.","journal-title":"Clin Cancer Res"},{"key":"14117_CR17","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021;27:4685\u20139.","journal-title":"Clin Cancer Res"},{"key":"14117_CR18","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.3390\/ijms20215319","volume":"20","author":"F Pagani","year":"2019","unstructured":"Pagani F, Randon G, Guarini V, et al. The landscape of actionable gene fusions in colorectal cancer. Int J Mol Sci. 2019;20:5319.","journal-title":"Int J Mol Sci"},{"key":"14117_CR19","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1016\/j.annonc.2022.04.430","volume":"33","author":"E Garralda","year":"2022","unstructured":"Garralda E, Hong D, Xu R, et al. SO-31 Long-term efficacy and safety of larotrectinib in patients with Tropomyosin receptor kinase (TRK) fusion Gastrointestinal (GI) cancer: an expanded dataset. Ann Oncol. 2022;33:S370.","journal-title":"Ann Oncol"},{"key":"14117_CR20","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1158\/0008-5472.CAN-16-3563","volume":"77","author":"WP Kloosterman","year":"2017","unstructured":"Kloosterman WP, van den Coebergh RRJ, Pieterse M, et al. A systematic analysis of oncogenic gene fusions in primary colon cancer. Cancer Res. 2017;77:3814\u201322.","journal-title":"Cancer Res"},{"key":"14117_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12967-021-03108-6","volume":"19","author":"J Wang","year":"2021","unstructured":"Wang J, Li R, Li J, et al. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing. J Transl Med. 2021;19:433.","journal-title":"J Transl Med"},{"key":"14117_CR22","doi-asserted-by":"crossref","unstructured":"Pietrantonio F, Di Nicolantonio F, Schrock AB et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J Natl Cancer Inst 2017;109.","DOI":"10.1093\/jnci\/djx089"},{"key":"14117_CR23","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/1078-0432.CCR-23-2693","volume":"30","author":"PM Kasi","year":"2024","unstructured":"Kasi PM, Lee JK, Pasquina LW, et al. Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types. Clin Cancer Res. 2024;30:836\u201348.","journal-title":"Clin Cancer Res"},{"key":"14117_CR24","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","volume":"24","author":"Y Hu","year":"2018","unstructured":"Hu Y, Ulrich BC, Supplee J, et al. False-Positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24:4437\u201343.","journal-title":"Clin Cancer Res"},{"key":"14117_CR25","doi-asserted-by":"crossref","unstructured":"Yen J, Drusbosky L, Weipert C et al. Abstract P5-13-29: analytical and clinical validation of a ctdna assay for detecting copy number loss and structural rearrangement variants contributing to homologous recombination and repair (HRR) deficiency. Cancer Res. 2022;82:P5-13\u201329.","DOI":"10.1158\/1538-7445.SABCS21-P5-13-29"},{"key":"14117_CR26","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/S0959-8049(22)01110-8","volume":"174","author":"A Schram","year":"2022","unstructured":"Schram A, Borad M, Sahai V, et al. Identifying FGFR2 fusions\/rearrangements in cholangiocarcinoma patients using a novel CfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor. Eur J Cancer. 2022;174:S116.","journal-title":"Eur J Cancer"},{"key":"14117_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. J Mol Diagn. 2017;19:4\u201323.","journal-title":"J Mol Diagn"},{"key":"14117_CR28","doi-asserted-by":"crossref","unstructured":"Oa Z, Kc B, Sr F et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients [Internet]. Clinical cancer research: an official journal of the American Association for Cancer Research 24, 2018[cited 2024 Dec 17] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29776953\/","DOI":"10.1158\/1078-0432.CCR-17-3837"},{"key":"14117_CR29","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-19-1324","volume":"25","author":"J Willis","year":"2019","unstructured":"Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive Plasma-Based genotyping panel. Clin Cancer Res. 2019;25:7035\u201345.","journal-title":"Clin Cancer Res"},{"key":"14117_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/annonc\/mdy509","volume":"30","author":"CM Parseghian","year":"2019","unstructured":"Parseghian CM, Loree JM, Morris VK, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30:243\u20139.","journal-title":"Ann Oncol"},{"key":"14117_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-020-00139-y","volume":"5","author":"CB Westphalen","year":"2021","unstructured":"Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. Npj Precis Onc. 2021;5:1\u20139.","journal-title":"Npj Precis Onc"},{"key":"14117_CR32","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","volume":"31","author":"R Bahleda","year":"2020","unstructured":"Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020;31:1405\u201312.","journal-title":"Ann Oncol"},{"key":"14117_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Bahleda R, Hierro C, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: A phase I Dose-Expansion study. Cancer Discov. 2022;12:402\u201315.","journal-title":"Cancer Discov"},{"key":"14117_CR34","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1158\/1078-0432.CCR-20-4073","volume":"27","author":"H Singh","year":"2021","unstructured":"Singh H, Li YY, Spurr LF, et al. Molecular characterization and therapeutic targeting of colorectal cancers harboring receptor tyrosine kinase fusions. Clin Cancer Res. 2021;27:1695\u2013705.","journal-title":"Clin Cancer Res"},{"key":"14117_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.humpath.2021.05.006","volume":"114","author":"C Bocciarelli","year":"2021","unstructured":"Bocciarelli C, Caumont C, Samaison L, et al. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. Hum Pathol. 2021;114:99\u2013109.","journal-title":"Hum Pathol"},{"key":"14117_CR36","doi-asserted-by":"publisher","first-page":"39945","DOI":"10.18632\/oncotarget.18098","volume":"8","author":"S Deihimi","year":"2017","unstructured":"Deihimi S, Lev A, Slifker M, et al. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 2017;8:39945\u201362.","journal-title":"Oncotarget"},{"key":"14117_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10020-022-00469-6","volume":"28","author":"S Zhao","year":"2022","unstructured":"Zhao S, Wu W, Jiang Z, et al. Roles of ARID1A variations in colorectal cancer: a collaborative review. Mol Med. 2022;28:42.","journal-title":"Mol Med"},{"key":"14117_CR38","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/0008-5472.CAN-22-0985","volume":"82","author":"CH Marshall","year":"2022","unstructured":"Marshall CH, Gondek LP, Luo J, et al. Clonal hematopoiesis of indeterminate potential in patients with solid tumor malignancies. Cancer Res. 2022;82:4107\u201313.","journal-title":"Cancer Res"},{"key":"14117_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"14117_CR40","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","volume":"1","author":"N Roper","year":"2020","unstructured":"Roper N, Brown A-L, Wei JS, et al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. 2020;1:100007.","journal-title":"Cell Rep Med"},{"key":"14117_CR41","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to Palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8:1390\u2013403.","journal-title":"Cancer Discov"},{"key":"14117_CR42","doi-asserted-by":"publisher","first-page":"108445","DOI":"10.1016\/j.mrrev.2022.108445","volume":"790","author":"SA Chakraborty","year":"2022","unstructured":"Chakraborty SA, Patnaik A. Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer. Mutat Res Rev Mutat Res. 2022;790:108445.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"14117_CR43","doi-asserted-by":"publisher","first-page":"6899","DOI":"10.1158\/1078-0432.CCR-19-0823","volume":"25","author":"CM Parseghian","year":"2019","unstructured":"Parseghian CM, Napolitano S, Loree JM, et al. Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on Rechallenge therapies. Clin Cancer Res. 2019;25:6899\u2013908.","journal-title":"Clin Cancer Res"},{"key":"14117_CR44","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.22.01423","volume":"41","author":"CM Parseghian","year":"2023","unstructured":"Parseghian CM, Sun R, Woods M, et al. Resistance mechanisms to Anti-Epidermal growth factor receptor therapy in RAS\/RAF Wild-Type colorectal cancer vary by regimen and line of therapy. J Clin Oncol. 2023;41:460\u201371.","journal-title":"J Clin Oncol"},{"key":"14117_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13058-021-01461-4","volume":"23","author":"NJ Chew","year":"2021","unstructured":"Chew NJ, Lim Kam Sian TCC, Nguyen EV, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast Cancer Res. 2021;23:82.","journal-title":"Breast Cancer Res"},{"key":"14117_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12885-016-2088-5","volume":"16","author":"W Liang","year":"2016","unstructured":"Liang W, He Q, Chen Y, et al. Metastatic EML4-ALK fusion detected by Circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report. BMC Cancer. 2016;16:62.","journal-title":"BMC Cancer"},{"key":"14117_CR47","first-page":"2845","volume":"60","author":"G Bunone","year":"2000","unstructured":"Bunone G, Uggeri M, Mondellini P, et al. RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res. 2000;60:2845\u20139.","journal-title":"Cancer Res"},{"key":"14117_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","volume":"173","author":"YB Khotskaya","year":"2017","unstructured":"Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58\u201366.","journal-title":"Pharmacol Ther"},{"key":"14117_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/21541248.2015.1131803","volume":"7","author":"G Hrustanovic","year":"2016","unstructured":"Hrustanovic G, Bivona TG. RAS signaling in ALK fusion lung cancer. Small GTPases. 2016;7:32\u20133.","journal-title":"Small GTPases"},{"key":"14117_CR50","doi-asserted-by":"publisher","first-page":"eabm8729","DOI":"10.1126\/scitranslmed.abm8729","volume":"15","author":"L Fairchild","year":"2023","unstructured":"Fairchild L, Whalen J, D\u2019Aco K, et al. Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Sci Transl Med. 2023;15:eabm8729.","journal-title":"Sci Transl Med"},{"key":"14117_CR51","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3390\/cancers12082277","volume":"12","author":"HT Chan","year":"2020","unstructured":"Chan HT, Chin YM, Nakamura Y, et al. Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications. Cancers (Basel). 2020;12:2277.","journal-title":"Cancers (Basel)"},{"key":"14117_CR52","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219\u201326.","journal-title":"Nat Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14117-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:52:27Z","timestamp":1757274747000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14117-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14117"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14117-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Advarra Institutional Review Board for the generation of de-identified data sets for research. All work was conducted in accordance with the Declaration of Helsinki. Human investigations were performed after approval by a local human investigations committee and in accordance with an assurance filed with and approved by the Department of Health and Human Services, where appropriate. Informed Consent was obtained from all patients and\/or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Reagan M Barnett reports employment at Guardant Health and stock\/ownership interest in Guardant Health. Sante Gnerre reports employment at Guardant Health and stock\/ownership interest in Guardant Health. Kristin Edwards reports employment at Guardant Health and stock\/ownership interest in Guardant Health. Jason A Willis Reports Honoraria from Bayer and Cor2Ed. Michael J Overmann reports consulting\/advisory roles at 3D Medicines, Array BioPharma, Bristol-Myers Squibb, Eisai, Gritstone Bio, Janssen Medimmune, Merck, Novartis, Pfizer, Promega, Roche\/Genentech, Spectrum Pharmaceuticals and Research funding from Bristol-Myers Squibb, MedImmune, Merck, Roche. Kanwal Raghav Reports consulting\/advisory roles at 3D Medicines, Array BioPharma, Bristol-Myers Squibb, Eisai, Gritstone Bio, Jansssen, MedImmune, Merck, Novartis, Pfizer, Promega, Roche\/Genentech, Spectrum Pharmaceuticals and Research funding from Bristol-Myers Squibb, MedImmune, Merck and Roche. Arvind Dasari reports consulting\/advisory roles at HutcMed, Illumina\/Grail, Personalis, SIRTIS, Takeda and Research funding from Eisai, Guardant Health, Hutchison MediPharma, Merck, Natera, Xencor and travel\/accommodations\/expenses from Hutchison MediPharma, Takeda. Leylah Drusbosky reports employment at Guardant Health and stock\/ownership interest in Guardant Health. Scott Kopetz reports stock\/ownership interests in Frontier Medicines, Iylon, Lutris, Navire, Xilis and consulting\/advisory roles at Abbvie, Accademia Nazionale Di Medicina (ACCMED), Amal Therapeutics, Amgen, AstraZeneca\/MedImmune, AVEO, Bayer Health, Bicara Therapeutics, Black Diamond Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb\/Medarex, Cardiff Oncology, Carina Biotech, CureTeq, EMD Serono, Endeavor BioMedicines, Flame Biosciences, Foundation Medicine, Frontier Medicines, Genentech, Genomic Health, Gilead Sciences, GlaxoSmithKline, HalioDx, Harbinger Oncology Inc, Holy Stone Healthcare, Inivata, Ipsen, Iylon, Jacobio, Jazz Pharmaceuticals, JOnhson & Johnson\/Janssen, Lilly, Lutris, Merck, Mirati Therapeutics, NeoGenomics Laboratories, Novartis, Numab, Ono Pharmaceutical, Pfizer, Redx Pharma, Repare Therapeutics, Replimune, Roche, Sanofi, Servier, Tachyon Therapeutics, Taiho Pharmaceutical, Takeda, Tempus, Xilis, Zentalis and research funding from Amgen, Array BioPharma, Biocartis, Daiichi Sankyo, EMD Serono, Genentech\/Roche, Guardant Health, Lilly, MedImmune, Novartis, Sanofi. Van K Morris Reports consulting\/advisory role at Incyte, Regeneron and research funding from Bicara Therapeutics, BioNTech, Bristol-Myers-Squibb, EMD Serono, Novartis, Pfizer. The remaining authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1201"}}